[Federal Register Volume 59, Number 44 (Monday, March 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-5129]


[[Page Unknown]]

[Federal Register: March 7, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

 

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces a forthcoming meeting of a public 
advisory committee of the Food and Drug Administration (FDA). This 
notice also summarizes the procedures for the meeting and methods by 
which interested persons may participate in open public hearings before 
FDA's advisory committees.

MEETING: The following advisory committee meeting is announced:

Joint Meeting of the Antiviral Drugs and Nonprescription Drugs Advisory 
Committees

    Date, time, and place. May 19, 1994, 3:30 p.m., conference rms. D 
and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.
    Type of meeting and contact person. Open public hearing, 3:30 p.m. 
to 4:30 p.m., unless public participation does not last that long; open 
committee discussion, 4:30 p.m. to 6 p.m.; Lee L. Zwanziger, Mae 
Brooks, or Valerie Mealy, Center for Drug Evaluation and Research (HFD-
9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 
20857, 301-443-4695.
    General function of the committees. The Antiviral Drugs Advisory 
Committee reviews and evaluates available data concerning the safety 
and effectiveness of marketed and investigational human drug products 
for use in the treatment of acquired immune deficiency syndrome (AIDS), 
AIDS-related complex (ARC), and other viral, fungal, and mycobacterial 
infections. The Nonprescription Drugs Advisory Committee reviews and 
evaluates available data concerning the safety and effectiveness of 
over-the-counter (nonprescription) human drug products for use in the 
treatment of a broad spectrum of human symptoms and diseases.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committees. Those desiring to make formal presentations should 
notify the contact person before May 9, 1994, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time required to make their comments. 
Those persons or groups presenting views on this topic at the public 
hearing before the Commissioner of Food and Drugs, earlier the same 
day, need not make a second presentation because views presented in the 
earlier meeting will be taken into consideration in this joint advisory 
committee meeting.
    Open committee discussion. The committees will discuss jointly the 
issues and concerns relating to over-the-counter availability of 
acyclovir for the treatment of recurrent genital herpes, taking into 
consideration the views expressed at the public hearing scheduled 
earlier the same day. (See a notice of public hearing on the proposed 
switch of acyclovir from prescription to over-the counter status 
published elsewhere in this issue of the Federal Register.)
    FDA public advisory committee meetings may have as many as four 
separable portions: (1) An open public hearing, (2) an open committee 
discussion, (3) a closed presentation of data, and (4) a closed 
committee deliberation. Every advisory committee meeting shall have an 
open public hearing portion. Whether or not it also includes any of the 
other three portions will depend upon the specific meeting involved. 
There are no closed portions for the meetings announced in this notice. 
The dates and times reserved for the open portions of each committee 
meeting are listed above.
    The open public hearing portion of each meeting shall be at least 1 
hour long unless public participation does not last that long. It is 
emphasized, however, that the 1 hour time limit for an open public 
hearing represents a minimum rather than a maximum time for public 
participation, and an open public hearing may last for whatever longer 
period the committee chairperson determines will facilitate the 
committee's work.
    Public hearings are subject to FDA's guideline (subpart C of 21 CFR 
part 10) concerning the policy and procedures for electronic media 
coverage of FDA's public administrative proceedings, including hearings 
before public advisory committees under 21 CFR part 14. Under 21 CFR 
10.205, representatives of the electronic media may be permitted, 
subject to certain limitations, to videotape, film, or otherwise record 
FDA's public administrative proceedings, including presentations by 
participants.
    Meetings of advisory committees shall be conducted, insofar as is 
practical, in accordance with the agenda published in this Federal 
Register notice. Changes in the agenda will be announced at the 
beginning of the open portion of a meeting.
    Any interested person who wishes to be assured of the right to make 
an oral presentation at the open public hearing portion of a meeting 
shall inform the contact person listed above, either orally or in 
writing, prior to the meeting. Any person attending the hearing who 
does not in advance of the meeting request an opportunity to speak will 
be allowed to make an oral presentation at the hearing's conclusion, if 
time permits, at the chairperson's discretion.
    The agenda, the questions to be addressed by the committee, and a 
current list of committee members will be available at the meeting 
location on the day of the meeting.
    Transcripts of the open portion of the meeting may be requested in 
writing from the Freedom of Information Office (HFI-35), Food and Drug 
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, 
approximately 15 working days after the meeting, at a cost of 10 cents 
per page. The transcript may be viewed at the Dockets Management Branch 
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., 
Rockville, MD 20857, approximately 15 working days after the meeting, 
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary 
minutes of the open portion of the meeting may be requested in writing 
from the Freedom of Information Office (address above) beginning 
approximately 90 days after the meeting.
    This notice is issued under section 10(a)(1) and (2) of the Federal 
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR 
part 14) on advisory committees.

    Dated: March 1, 1994.
Jane E. Henney,
Deputy Commissioner for Operations.
[FR Doc. 94-5129 Filed 3-2-94; 2:55 pm]
BILLING CODE 4160-01-F